News
Update of the Blue Book: What's New in the Treatment of Metastatic NSCLC with an ALK Gene Mutation?
As of March 1, 2022, the 28th update of the Blue Book by the Czech Society for Oncology of ČLS JEP was released. Let's take a look at what changes it has brought compared to the previous version in the treatment of metastatic non-small cell lung cancer (NSCLC) with a driver mutation in the ALK gene.
Brain Metastases Are Not an Absolute Contraindication for Antiplatelet Therapy
On one hand, there's a higher risk of thromboembolic events, and on the other, a higher risk of…
Complete remission of ALK-positive lung cancer in a patient after multiple lines of targeted therapy – a case study
Targeted treatment for driving oncogenic mutations has significantly improved outcomes for patients…
How Do Vaccinated MS Patients Fare with COVID-19 Antibodies?
Which disease-modifying drugs for the treatment of multiple sclerosis (MS) reduce the humoral…
When Teriflunomide and Interferon Join Forces
Progressive multifocal leukoencephalopathy is a nightmare for all doctors prescribing…
Fixed Combination of Tiotropium/Olodaterol in SMI Inhaler and Its Benefits in COPD Treatment
The TRONARTO study, whose conclusions were published in the International Journal of Chronic…
Protection of Ovarian Function During Breast Cancer Treatment
Women diagnosed with breast cancer of childbearing age are concerned about how to maintain ovarian…
New Antidiabetic Drugs in Cardiovascular Prevention in International Recommendations
Results from studies on new antidiabetic drugs showing cardiovascular (CV) benefits of…
Bite-Sized Pieces from EHA 2021: Two New Findings on T-Cell Lymphoma
Can a molecule that is crucial for the sensitivity of adult T-cell lymphoma or leukemia (ATLL) to…
Modern View on Schizophrenia Therapy Through the Lens of Lurasidone
At the psychiatric symposium titled 'Chance for a Better Quality of Life with a Schizophrenia…